Free Trial

Palisade Bio (PALI) FDA Approvals

Palisade Bio logo
$1.01 -0.01 (-0.98%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.00 -0.01 (-0.99%)
As of 08/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Palisade Bio's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Palisade Bio (PALI). Over the past two years, Palisade Bio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PALI-2108 and PDE4. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

PALI-2108 FDA Regulatory Timeline and Events

PALI-2108 is a drug developed by Palisade Bio for the following indication: For patients affected by UC. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

PDE4 FDA Regulatory Events

PDE4 is a drug developed by Palisade Bio for the following indication: For Patient Stratification. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Palisade Bio FDA Events - Frequently Asked Questions

In the past two years, Palisade Bio (PALI) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Palisade Bio (PALI) has reported FDA regulatory activity for the following drugs: PALI-2108 and PDE4.

The most recent FDA-related event for Palisade Bio occurred on July 31, 2025, involving PALI-2108. The update was categorized as "Provided Update," with the company reporting: "Palisade Bio, Inc. announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the Company's novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn's disease (FSCD) and moderate to severe ulcerative colitis (UC)."

Current therapies from Palisade Bio in review with the FDA target conditions such as:

  • For patients affected by UC. - PALI-2108
  • For Patient Stratification - PDE4

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:PALI) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners